Collplant Biotechnologies Ltd current report, Q4 FY2021

CollPlant Biotechnologies Ltd. Form 6-K Summary

Business Context and Reporting Period

This Form 6-K was filed by CollPlant Biotechnologies Ltd. on November 15, 2021, covering the month of November 2021. The filing serves to distribute a press release regarding the commercial launch of the company's BioInk Platform.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report of a corporate event rather than a financial statement.

Material Changes and Corporate Events

  • Commercial Launch: CollPlant announced the commercial launch of its BioInk Platform in collaboration with Collink.3D.
  • Application: The platform is designed for the 3D bioprinting of human tissues, scaffolds, and organs.
  • Regulatory Action: The first and second paragraphs and "Safe Harbor Statements" of the attached press release are incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3.

Guidance, Outlook, and Risks

The filing incorporates "Safe Harbor Statements" from the press release, indicating the presence of forward-looking statements regarding the commercial launch. The text does not provide specific numerical guidance, detailed management commentary on financial outlook, or a list of specific risks beyond the standard safe harbor language.

Investor Verification Checklist

  • Verify the terms of the collaboration agreement between CollPlant and Collink.3D.
  • Review the full text of the press release (Exhibit 99.1) for details on the BioInk Platform's technical specifications and market strategy.
  • Check subsequent filings for any financial impact or revenue recognition related to this commercial launch.
  • Confirm the status of the Registration Statements (Form S-8 and Form F-3) referenced in the incorporation by reference.